European Confederation of Medical Mycology (ECMM) prospective survey of cryptococcosis: Report from Italy

References

• Kwon-Chung KJ, Bennett JE. Cryptococcosis. In: Kwon-Chung KJ, Bennett JE, eds. Medical Mycology. Philadelphia, PA: Lea & Febiger, 1992: 430–431.
   Google Scholar
• Franzot SP, Salkin IF, Casadevall A. Cryptococcus neoformans var. grubii: separate varietal state for Cryptococcus neoformans serotype A isolates. J Clin Microbiol 1999; 37: 838–840.
   Google Scholar
• Bennett JE, Kwon-Chung KJ, Howard DH. Epidemiologic differences among serotypes of Cryptococcus neoformans. Am J Epidemiol 1977; 105: 582–586.
   PubMed Web of Science ®Google Scholar
• Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995; 21: 28–34.
   PubMed Web of Science ®Google Scholar
• Dromer F, Mathoulin S, Dupont B, et aL Epidemiology of cryptococcosis in France: a 9 year survey (1985-1993). Clin Infect Dis 1996; 23: 82–90.
   PubMed Web of Science ®Google Scholar
• Hajjeh RA, Conn LA, Stephens DS, et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. J Infect Dis 1999; 179: 449–454.
   PubMed Web of Science ®Google Scholar
• Dismukes WE. Cryptococcal meningitis in patients with AIDS. J Infect Dis 1988; 157: 624–628.
   PubMed Web of Science ®Google Scholar
• Newton JA Jr, Tasker SA, Bone WD, et al. Weekly fluconazole for the suppression of recurrent thrush in HIV-seropositive patients: impact on the incidence of disseminated cryptococcal infection. AIDS 1995; 9: 1286–1287.
   PubMed Web of Science ®Google Scholar
• Costagliola D. Clinical Epidemiology Group from CISIH. Trends in incidence of clinical manifestations of HIV infection and antiretroviral prescriptions in French university hospitals [abstract 182]. In: 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1998.
   Google Scholar
• Chen S, Sorrel T, Nimmo G, et al. Epidemiology and host- and variety-dependent characteristics of infection due to Crypto-coccus neoformans in Australia and New Zealand. Clin Infect Dis 2000; 31: 499–508.
   PubMed Web of Science ®Google Scholar
• Viviani MA, Swinne D, Kouzmanov A, et al. Survey of cryptococcosis in Europe. The ECMM working group report [abstract WG-02]. Abstracts of the 6th Congress of the European Confederation of Medical Mycology, Barcelona 9–11 November 2000. Rev Iberoam Micol 2000; 17: S115.
   Google Scholar
• Barnett JA, Payne RW, Yarrow D. Yeasts: Characteristics and Identification, 2nd edn. Cambridge: Cambridge University Press, 1990.
   Google Scholar
• Viviani MA, Esposto MC, Cogliati M, et al. Isolation of a Cryptococcus neoformans serotype A MATa strain from the Italian environment. Med Mycol 2001; 39: 383–386.
   PubMed Web of Science ®Google Scholar
• Viviani MA, Wen H, Roverselli A, et al. Identification by polymerase chain reaction fingerprinting of Cryptococcus neoformans serotype AD. J Med Vet Mycol 1997; 35: 355–360.
   PubMedGoogle Scholar
• Cogliati M, Allaria M, Liberi G, et al. Sequence analysis and ploidy determination of Cryptococcus neoformans var. neofor-mans. J Mycol Mid 2000; 10: 171–176.
   Web of Science ®Google Scholar
• Cogliati M, Esposto MC, Clarke DL, et aL Origin of Crypto-coccus neoformans var. neoformans diploid strains. J Clin Microbiol 2001; 39: 3889–3894.
   PubMed Web of Science ®Google Scholar
• Lengeler KB, Cox GM, Heitman J. Serotype AD strains of Cryptococcus neoformans are diploid or aneuploid and are heterozygous at the mating-type locus. Infect Immun 2001; 69: 115–122.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Refer-ence Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M-27A. Vilanova, PA: National Committee for Clinical Laboratory Standards, 1997 117.
   Google Scholar
• Ghannoum M, Ibrahim AS, Fu Y, et al. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol 1992; 30: 2881–2886.
   PubMed Web of Science ®Google Scholar
• Esposto MC, Cogliati M, Tortorano AM, et al. The pH effect on the in vitro susceptibility of Cryptococcus neoformans to flucytosine (5FC): correlation of in vitro data with clinical outcome [abstract P029]. 5th International Conference on Cryptococcus and Cryptococcosis, Adelaide 3–7 March 2002.
   Google Scholar
• Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretative breakpoints for antifungal susceptibility testing: conceptual frame work and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infections. Clin Infect Dis 1997; 24: 235–247.
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Diaz-Guerra TM, Lellado E, et al. Flucyto-sine primary resistance in Candida species and Cryptococcus neoformans. Eur J Gun Microbiol Infect Dis 2001; 20: 276–279.
   PubMed Web of Science ®Google Scholar
• Tortorano AM, Viviani MA, Rigoni AL, et al. Prevalence of serotype D in Cryptococcus neofotmans isolates from HIV positive and HIV negative patients in Italy. Mycoses 1997; 40: 297–302.
   PubMed Web of Science ®Google Scholar
• White M, Cirrincione C, Blevins A, et al. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis 1992; 165: 960–963.
   PubMed Web of Science ®Google Scholar
• Holtzer CD, Jacobson MA, Hadley WK, et al. Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994-1997. AIDS 1998; 12: 1931-1933.
   Google Scholar
• Martinez E, Garcia-viejo MA, Marcos MA, et al. Discontinua-tion of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS 2000; 14: 2615–2617.
   PubMed Web of Science ®Google Scholar
• Woods ML II, Lacginley R, Eisen DP, et al. HIV combination therapy: partial immune restitution unmasking latent crypto-coccal infection. AIDS 1998; 12: 1491–1494.
   PubMed Web of Science ®Google Scholar
• Manfredi R, Pieri F, Pileri SA, et al. The changing face of AIDS-related opportunism: cryptococcosis in the highly active antiretroviral therapy (HAART) era. Case reports and litera-ture review. Mycopathologia 1999; 148: 73–78.
   PubMed Web of Science ®Google Scholar
• Backo M, Tomalty L, Wobeser W. The role of cryptococcal latex antigen tests. Clin Microbiol News 2001; 23(8): 64–66.
   Google Scholar
• Tintelnot K, Adler S, Bergmann F, et al. Case reports. Disseminated cryptococcosis without cryptococcal antigen detection. Mycoses 2000; 43: 203–207.
   Google Scholar
• Steembergen JN, Casadevall A. Prevalence of Cryptococcus neofotmans var. neoformans (serotype D) and Cryptococcus neofotmans var grubii (serotype A) isolates in New York City. J Gun Microbiol 2000; 38: 1974–1976.
   Google Scholar
• Cogliati M, Esposto MC, Liberi G, et al. Molecular epidemiol-ogy of cryptococcosis [abstract L-29]. Abstracts of the 6th Congress of the European Confederation of Medical Mycology, 9–11 November 2000 (Barcelona, Spain). Rev Iberoam Micol 2000; 17: S116.
   Google Scholar
• Boekout T, Theelen B, Diaz M, et al. Hybrid genotypes in the pathogenic yeast Cryptococcus neofotmans. Microbiology 2001; 147: 891–907.
   PubMed Web of Science ®Google Scholar
• Naka W, Masuda M, Konohana A, et al. Primary cutaneous cryptococcosis and Cryptococcus neofotmans serotype D. Clin Exp Dermatol 1995; 20: 221–225.
   PubMed Web of Science ®Google Scholar
• Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; & 515–548.
   Google Scholar
• Pfaller MA, Zhang J, Messer SA, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neofotmans from the United States and Africa. AAC 1999; 43: 169–171.
   Google Scholar
• Nguyen MB, Yu CY. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. AAC 1998; 42: 471–472.
   Google Scholar
• Polak A, Scholer HJ. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy 1975; 21: 113–130.
   PubMed Web of Science ®Google Scholar